________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.1
CML, chronic myeloid leukaemia; CP, chronic phase; Ph + CML, Philadelphia chromosome-positive chronic myeloid leukaemia; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitors.
For further information please refer to the Summary of Product Characteristics.
References
- SCEMBLIX (asciminib) Summary of Product Characteristics.
- Bosi GR, et al. Hematol Transfus Cell Ther 2019;41(3):222–228.
- Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
- Réa D, et al. Blood 2021;138(21):2031–2041.